Symbols / TOI $2.69 +3.07%
TOI Chart
About
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance services. The company also provides and manages clinical trials, palliative care programs, stem cell transplants services, other care delivery models associated with non-community-based academic, and tertiary care settings; and conducts clinical trials for a range of pharmaceutical, and medical device companies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Care Facilities | Market Cap | 264.65M |
| Enterprise Value | 332.74M | Income | -54.70M | Sales | 461.04M |
| Book/sh | -0.13 | Cash/sh | 0.28 | Dividend Yield | — |
| Payout | 0.00% | Employees | 825 | IPO | — |
| P/E | — | Forward P/E | -16.81 | PEG | — |
| P/S | 0.57 | P/B | -21.35 | P/C | — |
| EV/EBITDA | -9.76 | EV/Sales | 0.72 | Quick Ratio | 1.34 |
| Current Ratio | 1.68 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.64 | EPS next Y | -0.16 | EPS Growth | — |
| Revenue Growth | 36.70% | Earnings | 2026-03-12 | ROA | -14.99% |
| ROE | -41.32% | ROIC | — | Gross Margin | 14.82% |
| Oper. Margin | -5.90% | Profit Margin | -14.38% | Shs Outstand | 98.38M |
| Shs Float | 79.76M | Short Float | 11.08% | Short Ratio | 4.59 |
| Short Interest | — | 52W High | 4.88 | 52W Low | 0.63 |
| Beta | 0.21 | Avg Volume | 1.73M | Volume | 340.33K |
| Target Price | $6.50 | Recom | Strong_buy | Prev Close | $2.61 |
| Price | $2.69 | Change | 3.07% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.50
Mean price target
2. Current target
$2.69
Latest analyst target
3. DCF / Fair value
$-1.99
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.69
Low
$5.00
High
$8.00
Mean
$6.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-09 | reit | Needham | Buy → Buy | $5 |
| 2026-03-09 | reit | BTIG | Buy → Buy | $7 |
| 2025-11-25 | init | Needham | — → Buy | $5 |
| 2025-10-21 | reit | BTIG | Buy → Buy | $7 |
| 2025-07-16 | init | B. Riley Securities | — → Buy | $6 |
| 2023-06-16 | main | Guggenheim | — → Buy | $2 |
| 2023-03-20 | main | Guggenheim | — → Neutral | $3 |
| 2022-11-11 | main | Guggenheim | — → Buy | $6 |
| 2022-08-15 | init | Jefferies | — → Buy | $10 |
News
RSS: Latest TOI news- TOI: BTIG Reiterates Buy Rating, Maintains $7 Price Target | TOI Stock News - GuruFocus Mon, 09 Mar 2026 16
- Oncology Institute (NASDAQ:TOI) Receives "Buy" Rating from Needham & Company LLC - MarketBeat Mon, 09 Mar 2026 12
- Pharmacy CEO Kim Tzoumakas joins board of large U.S. cancer care group - Stock Titan Mon, 23 Feb 2026 08
- Investors Give The Oncology Institute, Inc. (NASDAQ:TOI) Shares A 26% Hiding - simplywall.st Mon, 02 Feb 2026 08
- Oncology Institute (TOI) Projected to Post Quarterly Earnings on Thursday - MarketBeat Sun, 08 Mar 2026 11
- Individual investors own 30% of Topicus.com Inc. (CVE:TOI) shares but public companies control 48% of the company - Yahoo Finance ue, 27 Jan 2026 08
- A Mysterious Stock Has Rallied Over 950% This Year. Here's 1 Key Reason Why Investors Are Turning Bullish - The Motley Fool Fri, 21 Nov 2025 08
- Needham Initiates Coverage of Oncology Institute (TOI) with Buy Recommendation - Nasdaq ue, 25 Nov 2025 08
- Reliance, Ambuja Cements & more: Top stocks to watch on March 10 - The Times of India ue, 10 Mar 2026 01
- The Oncology Institute (NASDAQ: TOI) sets earnings release and conference call for Nov. 13 - Stock Titan Wed, 22 Oct 2025 07
- Both individual investors who control a good portion of The Oncology Institute, Inc. (NASDAQ:TOI) along with institutions must be dismayed after last week's 13% decrease - simplywall.st hu, 06 Nov 2025 08
- Topicus.com (TSXV:TOI): Exploring Valuation After Recent Share Price Momentum - Yahoo Finance Mon, 27 Oct 2025 07
- Oncology Institute's (TOI) Buy Rating Reaffirmed at BTIG Research - MarketBeat Mon, 09 Mar 2026 12
- Cancer care group adds veteran CFO to its board of directors - Stock Titan Mon, 05 Jan 2026 08
- How Do Rising Revenues But Weaker Earnings Reframe Topicus.com’s (TSXV:TOI) Profitability Story? - simplywall.st ue, 03 Mar 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 247 | 879.0 | — | Sale at price 3.56 per share. | CARTER ROBERT ROSS | Chief Financial Officer | — | 2026-01-02 00:00:00 | D |
| 1 | 13333 | 50291.0 | — | Sale at price 3.77 per share. | HIVELY BRADFORD DANIEL | Director | — | 2025-12-15 00:00:00 | D |
| 2 | 81790 | — | — | Stock Award(Grant) at price 0.00 per share. | PACALA MARK L. | Director | — | 2025-11-20 00:00:00 | D |
| 3 | 91049 | — | — | Stock Award(Grant) at price 0.00 per share. | KAUSHAL MOHIT | Director | — | 2025-11-20 00:00:00 | D |
| 4 | 108024 | — | — | Stock Award(Grant) at price 0.00 per share. | MCGEORGE ANNE | Director | — | 2025-11-20 00:00:00 | D |
| 5 | 74074 | — | — | Stock Award(Grant) at price 0.00 per share. | HIVELY BRADFORD DANIEL | Director | — | 2025-11-20 00:00:00 | D |
| 6 | 84877 | — | — | Stock Award(Grant) at price 0.00 per share. | JOHNSON KAREN MARIE | Director | — | 2025-11-20 00:00:00 | D |
| 7 | 83333 | — | — | Stock Award(Grant) at price 0.00 per share. | LING GABRIEL | Director | — | 2025-11-20 00:00:00 | D |
| 8 | 50000 | 200000.0 | — | Sale at price 4.00 per share. | PACALA MARK L. | Director | — | 2025-11-18 00:00:00 | D |
| 9 | 6464 | — | — | Stock Award(Grant) at price 0.00 per share. | VIRNICH DANIEL | Chief Executive Officer | — | 2025-11-17 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | -6.70K | 15.85M | 1.94M |
| TaxRateForCalcs | 0.00 | 0.00 | 0.21 | 0.06 |
| NormalizedEBITDA | -54.20M | -54.98M | -67.09M | -41.47M |
| TotalUnusualItems | 3.32M | -15.47M | 75.50M | 33.53M |
| TotalUnusualItemsExcludingGoodwill | 3.32M | -15.47M | 75.50M | 33.53M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -64.66M | -83.07M | 152.00K | -10.93M |
| ReconciledDepreciation | 6.29M | 5.87M | 4.41M | 3.34M |
| ReconciledCostOfRevenue | 339.42M | 264.67M | 200.39M | 162.16M |
| EBITDA | -50.88M | -70.45M | 8.40M | -7.94M |
| EBIT | -57.17M | -76.33M | 3.99M | -11.28M |
| NetInterestIncome | -7.50M | -6.78M | -4.08M | -320.00K |
| InterestExpense | 7.50M | 6.78M | 4.08M | 320.00K |
| NormalizedIncome | -67.98M | -67.60M | -59.49M | -42.52M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -64.66M | -83.07M | 152.00K | -10.93M |
| TotalExpenses | 453.53M | 384.39M | 324.49M | 248.86M |
| TotalOperatingIncomeAsReported | -60.12M | -77.02M | -81.95M | -45.86M |
| DilutedAverageShares | 75.04M | 73.75M | 80.61M | 66.23M |
| BasicAverageShares | 75.04M | 73.75M | 72.79M | 66.23M |
| DilutedEPS | -0.71 | -0.92 | -0.20 | -0.16 |
| BasicEPS | -0.71 | -0.92 | 0.02 | -0.16 |
| DilutedNIAvailtoComStockholders | -53.01M | -67.88M | -16.98M | -10.63M |
| AverageDilutionEarnings | 0.00 | -17.05M | 0.00 | |
| NetIncomeCommonStockholders | -53.01M | -67.88M | 68.00K | -10.63M |
| OtherunderPreferredStockDividend | -11.66M | -15.19M | 84.00K | -299.00K |
| NetIncome | -64.66M | -83.07M | 152.00K | -10.93M |
| NetIncomeIncludingNoncontrollingInterests | -64.66M | -83.07M | 152.00K | -10.93M |
| NetIncomeContinuousOperations | -64.66M | -83.07M | 152.00K | -10.93M |
| TaxProvision | 0.00 | -36.00K | -243.00K | -671.00K |
| PretaxIncome | -64.66M | -83.10M | -91.00K | -11.60M |
| OtherIncomeExpense | 2.95M | -16.18M | 76.00M | 34.58M |
| OtherNonOperatingIncomeExpenses | -365.00K | -704.00K | 501.00K | 1.05M |
| SpecialIncomeCharges | 0.00 | -16.06M | 49.45M | 29.85M |
| OtherSpecialCharges | -183.00K | -4.96M | ||
| ImpairmentOfCapitalAssets | 0.00 | 16.87M | 9.94M | 0.00 |
| RestructuringAndMergernAcquisition | 0.00 | -803.00K | -59.22M | -24.89M |
| GainOnSaleOfSecurity | 3.32M | 592.00K | 26.04M | 3.69M |
| NetNonOperatingInterestIncomeExpense | -7.50M | -6.78M | -4.08M | -320.00K |
| InterestExpenseNonOperating | 7.50M | 6.78M | 4.08M | 320.00K |
| OperatingIncome | -60.12M | -60.15M | -72.01M | -45.86M |
| OperatingExpense | 114.11M | 119.72M | 124.10M | 86.71M |
| DepreciationAmortizationDepletionIncomeStatement | 6.29M | 5.87M | 4.41M | 3.34M |
| DepreciationAndAmortizationInIncomeStatement | 6.29M | 5.87M | 4.41M | 3.34M |
| SellingGeneralAndAdministration | 107.83M | 113.85M | 119.69M | 83.36M |
| GrossProfit | 54.00M | 59.57M | 52.09M | 40.85M |
| CostOfRevenue | 339.42M | 264.67M | 200.39M | 162.16M |
| TotalRevenue | 393.41M | 324.24M | 252.48M | 203.00M |
| OperatingRevenue | 393.41M | 324.24M | 252.48M | 203.00M |
| Line Item | 2024-12-31 | 2023-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 1.73M | 1.73M | ||
| OrdinarySharesNumber | 75.74M | 74.15M | 73.27M | 73.25M |
| ShareIssued | 77.47M | 75.88M | 73.27M | 73.25M |
| NetDebt | 43.46M | 53.34M | 66.61M | |
| TotalDebt | 123.15M | 119.67M | 108.18M | 183.00K |
| TangibleBookValue | -18.45M | 31.89M | 83.80M | 59.29M |
| InvestedCapital | 96.72M | 143.85M | 203.80M | 104.34M |
| WorkingCapital | 60.20M | 108.70M | 100.70M | 124.26M |
| NetTangibleAssets | -18.45M | 31.89M | 83.80M | 59.29M |
| CapitalLeaseObligations | 30.02M | 32.85M | 27.56M | 0.00 |
| CommonStockEquity | 3.59M | 57.02M | 123.17M | 104.16M |
| TotalCapitalization | 96.72M | 143.85M | 203.80M | 104.16M |
| TotalEquityGrossMinorityInterest | 3.59M | 57.02M | 123.17M | 104.16M |
| StockholdersEquity | 3.59M | 57.02M | 123.17M | 104.16M |
| TreasuryStock | 1.02M | 1.02M | 0.00 | |
| RetainedEarnings | -210.81M | -146.15M | -63.08M | -63.23M |
| AdditionalPaidInCapital | 215.41M | 204.19M | 186.25M | 167.39M |
| CapitalStock | 8.00K | 8.00K | 7.00K | 7.00K |
| CommonStock | 8.00K | 8.00K | 7.00K | 7.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 169.13M | 152.22M | 138.49M | 99.28M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 116.91M | 117.43M | 108.77M | 69.48M |
| OtherNonCurrentLiabilities | 125.00K | 365.00K | 868.00K | 6.90M |
| DerivativeProductLiabilities | 402.00K | 3.72M | 5.11M | 62.21M |
| NonCurrentDeferredLiabilities | 32.00K | 32.00K | 108.00K | 371.00K |
| NonCurrentDeferredTaxesLiabilities | 32.00K | 32.00K | 108.00K | 371.00K |
| LongTermDebtAndCapitalLeaseObligation | 116.35M | 113.31M | 102.68M | 0.00 |
| LongTermCapitalLeaseObligation | 23.22M | 26.49M | 22.06M | 0.00 |
| LongTermDebt | 93.13M | 86.83M | 80.62M | |
| CurrentLiabilities | 52.22M | 34.79M | 29.72M | 29.80M |
| OtherCurrentLiabilities | 3.60M | 3.23M | 2.64M | |
| CurrentDeferredLiabilities | 8.08M | 3.30M | 1.94M | 2.95M |
| CurrentDeferredRevenue | 4.70M | 1.09M | 1.14M | 592.00K |
| CurrentDebtAndCapitalLeaseObligation | 6.80M | 6.36M | 5.50M | 183.00K |
| CurrentCapitalLeaseObligation | 6.80M | 6.36M | 5.50M | 0.00 |
| CurrentDebt | 183.00K | |||
| LineOfCredit | 183.00K | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 6.97M | 5.52M | 5.31M | 3.33M |
| PayablesAndAccruedExpenses | 30.36M | 19.61M | 13.74M | 20.70M |
| CurrentAccruedExpenses | 6.04M | 5.18M | 4.11M | 5.01M |
| InterestPayable | 1.14M | 1.12M | 1.10M | |
| Payables | 24.32M | 14.43M | 9.63M | 15.69M |
| TotalTaxPayable | 0.00 | 255.00K | 132.00K | |
| IncomeTaxPayable | 0.00 | 255.00K | 132.00K | |
| AccountsPayable | 24.32M | 14.43M | 9.37M | 15.56M |
| TotalAssets | 172.72M | 209.24M | 261.67M | 203.44M |
| TotalNonCurrentAssets | 60.30M | 65.75M | 131.25M | 49.38M |
| OtherNonCurrentAssets | 589.00K | 561.00K | 477.00K | 320.00K |
| InvestmentsAndAdvances | 0.00 | 58.35M | 0.00 | |
| InvestmentinFinancialAssets | 0.00 | 58.35M | 0.00 | |
| AvailableForSaleSecurities | 58.35M | |||
| GoodwillAndOtherIntangibleAssets | 22.04M | 25.13M | 39.38M | 44.87M |
| OtherIntangibleAssets | 14.81M | 17.90M | 17.96M | 18.25M |
| Goodwill | 7.23M | 7.23M | 21.42M | 26.63M |
| NetPPE | 37.67M | 40.05M | 33.04M | 4.19M |
| AccumulatedDepreciation | -6.97M | -6.18M | -3.51M | -1.98M |
| GrossPPE | 44.64M | 46.23M | 36.55M | 6.18M |
| Leases | 12.50M | 9.21M | 6.66M | 3.39M |
| ConstructionInProgress | 106.00K | 1.80M | 1.14M | 518.00K |
| OtherProperties | 27.43M | 31.46M | 26.00M | 967.00K |
| MachineryFurnitureEquipment | 4.60M | 3.76M | 2.75M | 1.30M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 112.42M | 143.49M | 130.42M | 154.06M |
| OtherCurrentAssets | 4.03M | 4.05M | ||
| RestrictedCash | 0.00 | 875.00K | ||
| PrepaidAssets | 4.05M | 6.92M | 11.20M | |
| Inventory | 10.04M | 13.68M | 9.26M | 6.44M |
| FinishedGoods | 10.04M | 13.68M | 9.26M | 6.44M |
| Receivables | 48.68M | 42.91M | 40.43M | 21.24M |
| OtherReceivables | 346.00K | 551.00K | 343.00K | 1.24M |
| AccruedInterestReceivable | 242.00K | 274.00K | ||
| AccountsReceivable | 48.34M | 42.36M | 39.82M | 20.01M |
| CashCashEquivalentsAndShortTermInvestments | 49.67M | 82.86M | 73.81M | 114.30M |
| OtherShortTermInvestments | 0.00 | 49.37M | 59.80M | 0.00 |
| CashAndCashEquivalents | 49.67M | 33.49M | 14.01M | 114.30M |
| CashFinancial | 14.01M | 114.30M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -30.33M | -40.88M | -67.28M | -35.73M |
| RepurchaseOfCapitalStock | 0.00 | -1.02M | -9.00M | 0.00 |
| RepaymentOfDebt | -39.00K | -101.00K | -58.00K | -7.25M |
| IssuanceOfDebt | 0.00 | 110.00M | 0.00 | |
| IssuanceOfCapitalStock | 0.00 | 20.00M | ||
| CapitalExpenditure | -3.79M | -4.57M | -5.53M | -3.05M |
| InterestPaidSupplementalData | 4.50M | 4.51M | 224.00K | 275.00K |
| IncomeTaxPaidSupplementalData | 0.00 | 403.00K | 150.00K | 1.73M |
| EndCashPosition | 49.67M | 33.49M | 14.01M | 115.17M |
| BeginningCashPosition | 33.49M | 14.01M | 115.17M | 6.00M |
| ChangesInCash | 16.18M | 19.48M | -101.16M | 109.18M |
| FinancingCashFlow | -3.49M | -6.85M | 92.21M | 154.01M |
| CashFlowFromContinuingFinancingActivities | -3.49M | -6.85M | 92.21M | 154.01M |
| NetOtherFinancingCharges | -3.53M | -5.85M | -9.59M | 141.26M |
| ProceedsFromStockOptionExercised | 75.00K | 126.00K | 858.00K | 0.00 |
| NetPreferredStockIssuance | 0.00 | 20.00M | ||
| PreferredStockIssuance | 0.00 | 20.00M | ||
| NetCommonStockIssuance | 0.00 | -1.02M | -9.00M | 0.00 |
| CommonStockPayments | 0.00 | -1.02M | -9.00M | 0.00 |
| NetIssuancePaymentsOfDebt | -39.00K | -101.00K | 109.94M | -7.25M |
| NetLongTermDebtIssuance | -39.00K | -101.00K | 109.94M | -7.25M |
| LongTermDebtPayments | -39.00K | -101.00K | -58.00K | -7.25M |
| LongTermDebtIssuance | 0.00 | 110.00M | 0.00 | |
| InvestingCashFlow | 46.21M | 62.64M | -131.61M | -12.15M |
| CashFlowFromContinuingInvestingActivities | 46.21M | 62.64M | -131.61M | -12.15M |
| NetInvestmentPurchaseAndSale | 50.00M | 71.66M | -117.51M | 0.00 |
| SaleOfInvestment | 50.00M | 81.26M | 0.00 | |
| PurchaseOfInvestment | 0.00 | -9.60M | -117.51M | 0.00 |
| NetBusinessPurchaseAndSale | 0.00 | -4.46M | -8.58M | -9.11M |
| PurchaseOfBusiness | 0.00 | -4.46M | -8.58M | -9.11M |
| NetIntangiblesPurchaseAndSale | 0.00 | -200.00K | ||
| PurchaseOfIntangibles | 0.00 | -200.00K | ||
| NetPPEPurchaseAndSale | -3.79M | -4.57M | -5.53M | -2.85M |
| PurchaseOfPPE | -3.79M | -4.57M | -5.53M | -2.85M |
| OperatingCashFlow | -26.54M | -36.31M | -61.76M | -32.68M |
| CashFlowFromContinuingOperatingActivities | -26.54M | -36.31M | -61.76M | -32.68M |
| ChangeInWorkingCapital | 18.06M | 2.36M | -20.54M | -14.49M |
| ChangeInOtherCurrentLiabilities | -3.03M | -5.77M | -4.96M | 809.00K |
| ChangeInOtherCurrentAssets | 3.36M | 5.72M | 5.25M | -198.00K |
| ChangeInPayablesAndAccruedExpense | 18.69M | 8.16M | -3.71M | -1.18M |
| ChangeInAccruedExpense | 9.47M | 3.36M | 2.35M | -3.08M |
| ChangeInPayable | 9.21M | 4.80M | -6.06M | 1.90M |
| ChangeInAccountPayable | 9.21M | 5.06M | -6.19M | 2.92M |
| ChangeInTaxPayable | 0.00 | -255.00K | 123.00K | -1.01M |
| ChangeInIncomeTaxPayable | 0.00 | -255.00K | 123.00K | -1.01M |
| ChangeInPrepaidAssets | 1.18M | 3.13M | 4.28M | -9.09M |
| ChangeInInventory | 3.64M | -4.38M | -1.73M | -1.84M |
| ChangeInReceivables | -5.77M | -4.50M | -19.66M | -2.99M |
| ChangesInAccountReceivables | -5.97M | -4.56M | -20.29M | -2.19M |
| OtherNonCashItems | 6.30M | 5.40M | -56.77M | -24.84M |
| StockBasedCompensation | 11.15M | 17.81M | 27.68M | 24.54M |
| UnrealizedGainLossOnInvestmentSecurities | -133.00K | -249.00K | 378.00K | 0.00 |
| AssetImpairmentCharge | 0.00 | 18.89M | 10.42M | -417.00K |
| AmortizationOfSecurities | -500.00K | -2.63M | -1.02M | 0.00 |
| DeferredTax | 0.00 | -76.00K | -263.00K | -1.24M |
| DeferredIncomeTax | 0.00 | -76.00K | -263.00K | -1.24M |
| DepreciationAmortizationDepletion | 6.29M | 5.87M | 4.41M | 3.34M |
| DepreciationAndAmortization | 6.29M | 5.87M | 4.41M | 3.34M |
| OperatingGainsLosses | -3.04M | -622.00K | -26.20M | -8.64M |
| GainLossOnInvestmentSecurities | -3.32M | -592.00K | -26.04M | -3.69M |
| GainLossOnSaleOfPPE | 271.00K | -30.00K | 21.00K | 0.00 |
| NetIncomeFromContinuingOperations | -64.66M | -83.07M | 152.00K | -10.93M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TOI
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|